Skip to Content

Mechanistic evaluation of the androgen receptor inhibition driven hypoxic prostate microenvironment

School of Medicine, Dentistry and Biomedical Sciences | PHD

Applications are now CLOSED
Funding
Funded
Reference Number
SMED-2221-1197
Application Deadline
3 April 2022
Start Date
1 October 2022

Overview

Our research is aimed at understanding the mechanisms associated with AR-inhibition on the paracrine signalling between PTEN-deficient prostate tumour cells and AR-expressing endothelial cells in the TME vasculature. Prostate cancers are normally treated to inhibit the effects of over-active androgen signalling within prostate cells. Enzalutamide is one such agent and represents a class of drugs that can be grouped as androgen signalling inhibitors and develop to create a microenvironment that sustains cell growth and treatment resistance.

The sustained inhibition of androgen signalling in prostate cancer remains the treatment of choice for castrate-resistant prostate cancer (CRPC) (1). The Androgen Receptor (AR) plays a key role in driving prostate cancer progression. While initially beneficial, AR-targeted agents provide only a modest survival benefit. The development of resistance to these therapies remains a clinical problem, primarily attributed to the retention of active AR signalling in androgen-depleted conditions and failure to investigate the impact on the tumour microenvironment (TME).

There is increasing evidence that AR-signalling regulates the TME, whereby AR-inhibition results in rapid vascular atrophy and reduced micro-vessel density (MVD) in prostate tumours, partly as a result of vascular endothelial cell apoptosis.

Using several models of prostate cancer, we have shown that PTEN-loss results in the increased activity of cytokines which activate the receptors CXCR1/2. The CXCR2 receptor is expressed on prostate cancer cells and multiple immune cells surrounding the tumour. Our experimental work demonstrates that the inhibition of CXCR1/2 signalling increases the sensitivity of prostate cancer cells to AR-targeted agents, in part through multiple effects within the TME. The aim of this study is to evaluate the impact of PTEN-loss on the mechanisms by which prostate cancer cells respond to AR-targeted agents, with a focus on modulation of the TME.

Funding Information

Funded by Biotechnology and Biological Sciences Research Council (BBSRC). For UK domiciled students the value of an award includes the cost of approved tuition fees and maintenance support (Fees £4,500, Stipend £15,609 – 2022 TBC). To be considered eligible you must have been ordinarily resident in the UK for the full 3 year period prior to the start of the studentship and you must be ordinarily resident in Northern Ireland on the first day of the start of the studentship.
ROI (and EU applicants with pre-settled/settled) status may be eligible for funding if 3 year UK residency met.

Project Summary
Supervisor

Dr Melissa Wilson

Research Profile


Mode of Study

Full-time: 3 years


Funding Body
Biotechnology and Biological Sciences Research Cou
Apply now Register your interest